MBio Diagnostics Announces a License and Development Partnership with Roka Bioscience, Inc.
-- New collaboration to deliver on-the-spot, rapid, multiplex testing solutions with laboratory quality performance --
Boulder, CO, December 15, 2015 – MBio Diagnostics, Inc., a company leading a new era in rapid, on-the-spot clinical diagnostics and sample testing, today announced a product development partnership and licensing agreement with Roka Bioscience, Inc. (Nasdaq: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens. The partnership will cover certain exclusive and non-exclusive fields. MBio Diagnostics and Roka Bioscience will jointly carry out product development to capitalize on the strengths of both companies.
The MBio Array System utilizes MBio’s proprietary LightDeck® technology, which enables simple, multiplex testing in a compact system. This portable, easy-to-use multiplex reader can be placed into a wide variety of testing situations, including diverse locations across the food supply chain.
According to MBio CEO Chris Myatt, commercialization partnerships are an important aspect of MBio’s business strategy. “We have made enormous progress advancing our platform technology in recent years, and we are now executing on strategic partnerships that open new high-value opportunities,” said Myatt. “Recent high-profile cases of foodborne illness associated with fast food restaurants and supermarket ice cream clearly demonstrate the need for better food safety testing solutions. Our partnership with Roka positions MBio to help address this important public health need.”
About the MBio Array System
The MBio Array System is a portable, easy-to-use multiplex reader that provides lab-quality results in 1 to 20 minutes employing low-cost, disposable load-and-go cartridges. The System utilizes patented LightDeck® planar waveguide technology that eliminates sample prep and can be designed to detect all key analytes including: proteins, cells, nucleic acids, and small molecules.
About MBio Diagnostics
MBio Diagnostics is leading a new era in rapid, on-the-spot clinical diagnostics and sample testing. Our portable MBio Array System and disposable cartridges enable low-cost, rapid answers in 1 to 20 minutes. MBio aims to be the platform of choice for leading providers and users of clinical and analytical testing services in all market segments including: medical, veterinary, environmental, food, agricultural and military. www.mbiodx.com
MBio Diagnostics, Inc.
MacDougall Biomedical Communications